HIF1A and non-small cell lung carcinoma: Low dose erlotinib-cisplatin combination exhibits its anti-tumor activity by targeting angiogenesis through modulation of c-MYC/HIF-1α/VEGF pathway in non-small cell lung cancer cells with EGFR exon 19 deletions (39).